Avalyn Pharma Inc. (NASDAQ:AVLN) Receives Average Recommendation of “Buy” from Brokerages

Avalyn Pharma Inc. (NASDAQ:AVLN) has been assigned a consensus rating of “Buy” from the five research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $59.00.

Several analysts have recently commented on the company. Morgan Stanley began coverage on Avalyn Pharma in a research note on Tuesday, May 26th. They issued an “overweight” rating and a $53.00 target price for the company. Guggenheim initiated coverage on Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $80.00 price target on the stock. Jefferies Financial Group initiated coverage on Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $52.00 price target on the stock. Wall Street Zen upgraded Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th. Finally, Evercore initiated coverage on Avalyn Pharma in a research report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 target price on the stock.

Avalyn Pharma Stock Performance

Shares of NASDAQ AVLN opened at $35.46 on Wednesday. The company has a market capitalization of $1.57 billion and a price-to-earnings ratio of -1.62. The business’s fifty day moving average is $29.49. Avalyn Pharma has a 12-month low of $24.15 and a 12-month high of $35.84.

Avalyn Pharma (NASDAQ:AVLN) last posted its quarterly earnings results on Wednesday, June 3rd. The company reported ($21.83) earnings per share for the quarter, missing the consensus estimate of ($16.38) by ($5.45). As a group, equities analysts anticipate that Avalyn Pharma will post -3.45 EPS for the current year.

Institutional Trading of Avalyn Pharma

A hedge fund recently bought a new stake in Avalyn Pharma stock. Bank of New York Mellon Corp acquired a new stake in Avalyn Pharma Inc. (NASDAQ:AVLN) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 40,140 shares of the company’s stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned approximately 0.09% of Avalyn Pharma at the end of the most recent quarter.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.